ATE352618T1 - Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält - Google Patents

Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält

Info

Publication number: ATE352618T1
Authority: AT; Austria
Prior art keywords: receptor; cell death; proteins; domain responsible; antagonists
Prior art date: 1997-03-17

Application number

AT98912966T

Other languages

English (en)

Inventor

Jian Ni

Reiner L Gentz

Guo-Liang Yu

Jeffrey Y Su

Craig A Rosen

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-17

Filing date

1998-03-17

Publication date

2007-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26717514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE352618(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-03-17 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2007-02-15 Application granted granted Critical

2007-02-15 Publication of ATE352618T1 publication Critical patent/ATE352618T1/de

Links

230000030833 cell death Effects 0.000 title 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
239000005557 antagonist Substances 0.000 abstract 2
102000003390 tumor necrosis factor Human genes 0.000 abstract 2
108050001718 Death domains Proteins 0.000 abstract 1
102000010170 Death domains Human genes 0.000 abstract 1
101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 abstract 1
102000053594 human TNFRSF10B Human genes 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)

AT98912966T 1997-03-17 1998-03-17 Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält ATE352618T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4084697P	1997-03-17	1997-03-17
US5402197P	1997-07-29	1997-07-29

Publications (1)

Publication Number	Publication Date
ATE352618T1 true ATE352618T1 (de)	2007-02-15

Family

ID=26717514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98912966T ATE352618T1 (de)	1997-03-17	1998-03-17	Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält

Country Status (14)

Country	Link
US (2)	US7803615B1 (de)
EP (1)	EP0970213B1 (de)
JP (2)	JP4330180B2 (de)
KR (1)	KR100527638B1 (de)
CN (2)	CN1624128A (de)
AT (1)	ATE352618T1 (de)
AU (1)	AU747635B2 (de)
CA (2)	CA2644454A1 (de)
DE (1)	DE69836956T2 (de)
DK (1)	DK0970213T3 (de)
ES (1)	ES2281126T3 (de)
NZ (2)	NZ337795A (de)
PT (1)	PT970213E (de)
WO (1)	WO1998041629A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
US7357927B2 (en)	1996-03-12	2008-04-15	Human Genome Sciences, Inc.	Death domain containing receptors
US6713061B1 (en)	1996-03-12	2004-03-30	Human Genome Sciences, Inc.	Death domain containing receptors
US6635743B1 (en)	1996-03-22	2003-10-21	Human Genome Sciences, Inc.	Apoptosis inducing molecule II and methods of use
US7964190B2 (en)	1996-03-22	2011-06-21	Human Genome Sciences, Inc.	Methods and compositions for decreasing T-cell activity
US8329179B2 (en)	1997-01-28	2012-12-11	Human Genome Sciences, Inc.	Death domain containing receptor 4 antibodies and methods
US7452538B2 (en)	1997-01-28	2008-11-18	Human Genome Sciences, Inc.	Death domain containing receptor 4 antibodies and methods
US6433147B1 (en)	1997-01-28	2002-08-13	Human Genome Sciences, Inc.	Death domain containing receptor-4
PT1012274E (pt)	1997-01-28	2007-08-14	Craig A Rosen	Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
US6072047A (en) *	1997-02-13	2000-06-06	Immunex Corporation	Receptor that binds trail
US7528239B1 (en) *	1997-02-13	2009-05-05	Immunex Corporation	Receptor that binds trail
US6872568B1 (en) *	1997-03-17	2005-03-29	Human Genome Sciences, Inc.	Death domain containing receptor 5 antibodies
US20050233958A1 (en) *	1997-03-17	2005-10-20	Human Genome Sciences, Inc.	Death domain containing receptor 5
US20080248046A1 (en) *	1997-03-17	2008-10-09	Human Genome Sciences, Inc.	Death domain containing receptor 5
JP4330180B2 (ja)	1997-03-17	2009-09-16	ヒューマンジノームサイエンシーズ，インコーポレイテッド	死ドメイン含有レセプター５
US20100152426A1 (en) *	1997-05-15	2010-06-17	Ashkenazi Avi J	Apo-2 receptor fusion proteins
US6342369B1 (en) *	1997-05-15	2002-01-29	Genentech, Inc.	Apo-2-receptor
ES2293682T5 (es) *	1997-05-15	2011-11-17	Genentech, Inc.	Anticuerpo anti-apo2.
WO1999011791A2 (en) *	1997-09-05	1999-03-11	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2301173C (en) *	1997-09-12	2015-04-14	Biogen, Inc.	Cysteine rich receptors-train
WO2001060397A1 (en)	2000-02-16	2001-08-23	Genentech, Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
ATE443723T1 (de) *	1998-06-12	2009-10-15	Genentech Inc	Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
AU3501700A (en)	1999-02-26	2000-09-14	Human Genome Sciences, Inc.	Human endokine alpha and methods of use
JP2002543151A (ja) *	1999-05-04	2002-12-17	ヒューマンジノームサイエンシーズ，インコーポレイテッド	死ドメイン含有レセプター５
EP1212413A1 (de) *	1999-08-25	2002-06-12	Genome Therapeutics Corporation	Eine transmembranfalle zur isolierung von membrangebundenen proteinen
MXPA02007787A (es) *	2000-02-11	2004-09-10	Inst Genetics Llc	Moleculas trade y uso relacionado con las mismas.
JP2003531588A (ja)	2000-04-11	2003-10-28	ジェネンテック・インコーポレーテッド	多価抗体とその用途
US7476383B2 (en)	2000-05-02	2009-01-13	The Uab Research Foundation	Antibody selective for DR4 and uses thereof
US7279160B2 (en)	2000-05-02	2007-10-09	The Uab Research Foundation	Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en)	2000-05-02	2010-01-01	Uab Research Foundation	An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
EP2431054A3 (de)	2000-06-15	2013-03-06	Human Genome Sciences, Inc.	Menschlicher Tumornekrosefaktor Delta und Ypsilon
PT2281843T (pt)	2000-06-16	2017-01-02	Human Genome Sciences Inc	Anticorpos que se ligam imunoespecificamente a blys
DE60136816D1 (de)	2000-07-27	2009-01-15	Genentech Inc	Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US20060062786A1 (en) *	2000-11-08	2006-03-23	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) *	2000-11-08	2003-12-11	Theodora Salcedo	Antibodies that immunospecifically bind to TRAIL receptors
US7115717B2 (en)	2001-05-18	2006-10-03	Kirin Beer Kabushiki Kaisha	Anti-TRAIL-R antibodies
US7361341B2 (en)	2001-05-25	2008-04-22	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en)	2001-05-25	2008-03-25	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) *	2001-05-25	2005-06-16	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to TRAIL receptors
US7064189B2 (en)	2001-05-25	2006-06-20	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) *	2001-05-25	2009-09-10	Human Genome Sciences, Inc.	Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) *	2001-05-25	2005-09-29	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to TRAIL receptors
EP1409544B1 (de)	2001-07-03	2009-06-17	Genentech, Inc.	Humane dr4-antikörper und deren anwendungen
WO2003011318A1 (en) *	2001-08-01	2003-02-13	Genset S.A.	Agonists and antagonists of famoset for use in the treatment of metabolic disorders
EP1501866A4 (de)	2001-10-02	2006-02-08	Genentech Inc	Varianten des liganden apo-2 und verwendungen davon
JPWO2003038087A1 (ja)	2001-10-04	2005-02-24	関西ティー・エル・オー株式会社	ＤＲ５遺伝子のプロモーターおよびＳｉａｈ−１遺伝子のプロモーター
EP1450847B1 (de)	2001-11-13	2010-09-29	Genentech, Inc.	Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
US7741285B2 (en)	2001-11-13	2010-06-22	Genentech, Inc.	APO-2 ligand/trail formulations
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
AU2002361784A1 (en) *	2001-12-20	2003-07-09	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
US20040101915A1 (en) *	2002-06-18	2004-05-27	Irm Llc, A Delaware Limited Liability Company	Diagnosis and treatment of chemoresistant tumors
EP2500032A1 (de)	2002-06-24	2012-09-19	Genentech, Inc.	APO-2-Liganden-/Trailvarianten und Verwendungen dafür
KR20060132006A (ko)	2004-03-23	2006-12-20	비오겐 아이덱 엠에이 아이엔씨.	수용체 커플링제 및 이의 치료적 용도
MX2007001469A (es)	2004-08-06	2007-03-26	Genentech Inc	Ensayos y metodos que utilizan biomarcadores.
CN101061238B (zh) *	2004-08-06	2013-11-20	健泰科生物技术公司	使用生物标志的测定法和方法
JP2008513367A (ja) *	2004-09-08	2008-05-01	ジェネンテック・インコーポレーテッド	デスレセプターリガンド及びｃｄ２０抗体の使用方法
US20090175854A1 (en) *	2004-09-08	2009-07-09	Genentech, Inc.	Methods of using death receptor ligands and CD20 antibodies
JO3000B1 (ar) *	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
JP5562521B2 (ja)	2005-02-02	2014-07-30	ザユーエービーリサーチファンデーション	アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法
US8029783B2 (en)	2005-02-02	2011-10-04	Genentech, Inc.	DR5 antibodies and articles of manufacture containing same
CN101287990B (zh)	2005-08-16	2012-07-04	健泰科生物技术公司	通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
PE20071101A1 (es) *	2005-08-31	2007-12-21	Amgen Inc	Polipeptidos y anticuerpos
WO2007142667A2 (en)	2005-10-13	2007-12-13	Human Genome Sciences, Inc.	Treatment of patients with autoantibody positive disease
ES2618543T3 (es)	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
JP2012504969A (ja)	2008-10-10	2012-03-01	アナフォアインコーポレイテッド	Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
US8790663B2 (en)	2009-04-03	2014-07-29	Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences	Antigenic determinants of human death receptor DR5
US8906231B2 (en)	2009-09-10	2014-12-09	Lonza Biologics Plc	Method and system for polypeptide purification
CA2780130A1 (en)	2009-11-05	2011-05-12	The Uab Research Foundation	Treating basal-like genotype cancers
US8703712B2 (en)	2010-03-18	2014-04-22	The Uab Research Foundation	Targeting cancer stem cells with DR5 agonists
PH12013500845A1 (en)	2010-10-29	2013-06-24	Daiichi Sankyo Co Ltd	Novel anti-dr5 antibody
SG191716A1 (en)	2010-11-19	2013-08-30	Toshio Imai	Neutralizing anti-ccl20 antibodies
CA2828405A1 (en)	2011-02-28	2012-09-07	Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale	Apoptosis-inducing molecules and uses therefor
EP2704735A1 (de)	2011-05-03	2014-03-12	Genentech, Inc.	Vaskuläre disruptoren und ihre verwendung
WO2014159562A1 (en)	2013-03-14	2014-10-02	Bristol-Myers Squibb Company	Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
RU2679295C2 (ru)	2013-03-22	2019-02-06	Конинклейке Филипс Н.В.	Неинвазивное устройство для лечения кожи лазерным светом
CN104693308B (zh) *	2013-12-05	2020-08-04	同济大学	感受胞内pH变化的Smad5蛋白及其应用
EP3323428A1 (de)	2016-11-17	2018-05-23	CNRS Centre National de la Recherche Scientifique	Selektive c-flip-hemmer als antikrebsmittel
CN108997503B (zh) *	2017-06-06	2021-07-23	深圳市中科艾深医药有限公司	人sDR5-Fc重组融合蛋白及其作为制备治疗生殖系统炎症的药物中的应用
EP3910331A1 (de)	2020-05-15	2021-11-17	iOmx Therapeutics AG	Intrazelluläre kinase in verbindung mit resistenz gegen t-zell-vermittelte zytotoxizität und verwendungen davon
EP4257132A1 (de)	2022-04-08	2023-10-11	iOmx Therapeutics AG	Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
WO2024175554A1 (en)	2023-02-21	2024-08-29	Institut Curie	Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4002531A (en) *	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US5807715A (en) *	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5349053A (en) *	1990-06-01	1994-09-20	Protein Design Labs, Inc.	Chimeric ligand/immunoglobulin molecules and their uses
CA2067031C (en) *	1991-04-26	2003-02-18	Shigekazu Nagata	Dna coding for human cell surface antigen
IL99120A0 (en) *	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5565332A (en) *	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5447851B1 (en) *	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
GB9214857D0 (en) *	1992-07-13	1992-08-26	Medical Res Council	Human nucleic acid fragments and their use
US5643575A (en) *	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
DK1666591T3 (da) *	1995-06-29	2011-05-23	Immunex Corp	Cytokin der inducerer apoptose
PT1012274E (pt)	1997-01-28	2007-08-14	Craig A Rosen	Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
US6433147B1 (en)	1997-01-28	2002-08-13	Human Genome Sciences, Inc.	Death domain containing receptor-4
US6072047A (en)	1997-02-13	2000-06-06	Immunex Corporation	Receptor that binds trail
US20020160446A1 (en)	2000-11-14	2002-10-31	Holtzman Douglas A.	Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US20010010924A1 (en) *	1997-03-14	2001-08-02	Keith Charles Deen	Tumor necrosis factor related receptor, tr6 polynecleotides
US6313269B1 (en)	1997-03-14	2001-11-06	Smithkline Beecham Corporation	Tumor necrosis factor related receptor, TR6
JP4330180B2 (ja)	1997-03-17	2009-09-16	ヒューマンジノームサイエンシーズ，インコーポレイテッド	死ドメイン含有レセプター５
US6872568B1 (en)	1997-03-17	2005-03-29	Human Genome Sciences, Inc.	Death domain containing receptor 5 antibodies
AU7126498A (en)	1997-04-16	1998-11-11	Millennium Pharmaceuticals, Inc.	Tumor necrosis factor receptor related proteins tango-63d and tango-63e
US6342369B1 (en)	1997-05-15	2002-01-29	Genentech, Inc.	Apo-2-receptor
ES2293682T5 (es)	1997-05-15	2011-11-17	Genentech, Inc.	Anticuerpo anti-apo2.
IL133122A0 (en)	1997-06-18	2001-03-19	Genentech Inc	Apo-2dcr polypeptides
WO1999000423A1 (en)	1997-06-26	1999-01-07	Immunex Corporation	Protein that binds trail
EP1181319B1 (de)	1999-05-28	2009-04-22	Genentech, Inc.	Chimärische dr4 antikörper und ihre verwendung
ATE330972T1 (de)	1999-06-09	2006-07-15	Genentech Inc	Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
TWI318983B (en)	2000-05-02	2010-01-01	Uab Research Foundation	An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

1998
- 1998-03-17 JP JP54079098A patent/JP4330180B2/ja not_active Expired - Fee Related
- 1998-03-17 CN CNA2004100949179A patent/CN1624128A/zh active Pending
- 1998-03-17 DK DK98912966T patent/DK0970213T3/da active
- 1998-03-17 NZ NZ337795A patent/NZ337795A/en not_active IP Right Cessation
- 1998-03-17 AU AU67635/98A patent/AU747635B2/en not_active Withdrawn - After Issue
- 1998-03-17 US US09/042,583 patent/US7803615B1/en not_active Expired - Fee Related
- 1998-03-17 PT PT98912966T patent/PT970213E/pt unknown
- 1998-03-17 EP EP98912966A patent/EP0970213B1/de not_active Revoked
- 1998-03-17 KR KR10-1999-7008466A patent/KR100527638B1/ko not_active Expired - Fee Related
- 1998-03-17 DE DE69836956T patent/DE69836956T2/de not_active Revoked
- 1998-03-17 NZ NZ508381A patent/NZ508381A/xx not_active IP Right Cessation
- 1998-03-17 ES ES98912966T patent/ES2281126T3/es not_active Expired - Lifetime
- 1998-03-17 AT AT98912966T patent/ATE352618T1/de active
- 1998-03-17 CN CNB988045370A patent/CN1184315C/zh not_active Expired - Lifetime
- 1998-03-17 WO PCT/US1998/005377 patent/WO1998041629A2/en not_active Ceased
- 1998-03-17 CA CA002644454A patent/CA2644454A1/en not_active Abandoned
- 1998-03-17 CA CA002285040A patent/CA2285040C/en not_active Expired - Lifetime
2001
- 2001-12-07 US US10/005,842 patent/US20020098550A1/en not_active Abandoned
2007
- 2007-10-03 JP JP2007260427A patent/JP2008081503A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
WO1998041629A3 (en)	1998-10-29
DK0970213T3 (da)	2007-05-21
JP2001520513A (ja)	2001-10-30
US7803615B1 (en)	2010-09-28
AU6763598A (en)	1998-10-12
CA2285040A1 (en)	1998-09-24
CN1275162A (zh)	2000-11-29
KR20000076364A (ko)	2000-12-26
KR100527638B1 (ko)	2005-11-23
AU747635B2 (en)	2002-05-16
CN1184315C (zh)	2005-01-12
JP4330180B2 (ja)	2009-09-16
PT970213E (pt)	2007-04-30
WO1998041629A2 (en)	1998-09-24
EP0970213B1 (de)	2007-01-24
NZ337795A (en)	2001-06-29
JP2008081503A (ja)	2008-04-10
US20020098550A1 (en)	2002-07-25
CA2644454A1 (en)	1998-09-24
DE69836956T2 (de)	2007-10-31
NZ508381A (en)	2002-09-27
CA2285040C (en)	2009-01-27
CN1624128A (zh)	2005-06-08
DE69836956D1 (de)	2007-03-15
ES2281126T3 (es)	2007-09-16
HK1025352A1 (en)	2000-11-10
EP0970213A2 (de)	2000-01-12

Legal Events

Date

Code

Title

Description

2007-08-15

UEP

Publication of translation of european patent specification

Ref document number: 0970213

Country of ref document: EP

Publication	Publication Date	Title
ATE352618T1 (de)	2007-02-15	Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
DE69834027D1 (de)	2006-05-18	Tumor-nekrose-faktor rezeptor 5
AU6250098A (en)	1998-08-18	Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
DE69837996D1 (de)	2007-08-09	Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69841140D1 (de)	2009-10-22	Interleukin-17 rezeptor-ähnliches protein
WO2001055301A8 (en)	2001-09-07	Nucleic acids, proteins, and antibodies
WO2000066156A8 (en)	2001-07-26	Death domain containing receptor 5
WO2001054472A3 (en)	2002-01-31	Nucleic acids, proteins, and antibodies
WO2001055306A3 (en)	2001-12-20	Nucleic acids, proteins, and antibodies
EP1003767A4 (de)	2003-01-02	Menschlicher tumornekrosefaktor-rezeptor tr10
EP1178828A4 (de)	2004-10-13	"death-domain"enthaltender rezeptor
WO2001055168A8 (en)	2001-09-07	Nucleic acids, proteins and antibodies
ATE472599T1 (de)	2010-07-15	Chemokin alpha-5
WO1998027932A3 (en)	1999-01-28	Cerebellum and embryo specific protein
DE60027563D1 (de)	2006-06-01	Fc-Fusionsproteine des MENSCHLICHEN TUMOR-NEKROSE-FAKTOR-Rezeptors TR10
WO2001055167A8 (en)	2001-12-06	Nucleic acids, proteins, and antibodies
WO2002018622A3 (en)	2002-08-29	TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2001055162A8 (en)	2001-09-07	Nucleic acids, proteins, and antibodies
WO2001055305A3 (en)	2002-01-24	Nucleic acids, proteins, and antibodies